Semma Therapeutics IPO

Developer of trans-formative therapies designed to eliminate the use of insulin injections for type 1 diabetes patients. The company's trans-formative therapies is a cell-based therapy for diabetes which traditionally requires the use of an invasive insulin pump or multiple daily insulin injections combining proprietary cells with a state-of-the-art device to provide a replacement for the missing beta cells in a diabetic patient without immunosuppression, enabling doctors to provide a functional cure for patients with diabetes.

Register To Buy and Sell Shares

For more details on financing and valuation for Semma Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Updated on: Nov 15, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.